Advertisement

Journal of Infection and Chemotherapy

, Volume 18, Issue 5, pp 609–620 | Cite as

Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens’ antibacterial susceptibility

  • Akira Watanabe
  • Katsunori YanagiharaEmail author
  • Tetsuya Matsumoto
  • Shigeru Kohno
  • Nobuki Aoki
  • Toyoko Oguri
  • Junko Sato
  • Tetsuro Muratani
  • Morimasa Yagisawa
  • Kazuhiko Ogasawara
  • Naoto Koashi
  • Tsuneo Kozuki
  • Akira Komoto
  • Yoshisaburo Takahashi
  • Toshikatsu Tsuji
  • Michinori Terada
  • Kunio Nakanishi
  • Rikizo Hattori
  • Yukio Hirako
  • Akinori Maruo
  • Shinichi Minamitani
  • Kohei Morita
  • Tomotaro Wakamura
  • Keisuke Sunakawa
  • Hideaki Hanaki
  • Yoshinobu Ohsaki
  • Yasuhito Honda
  • Shoichi Sasaoka
  • Hiroaki Takeda
  • Hideki Ikeda
  • Atsuko Sugai
  • Makoto Miki
  • Susumu Nakanowatari
  • Hiroshi Takahashi
  • Mutsuko Utagawa
  • Nobuyuki Kobayashi
  • Jin Takasaki
  • Hisami Konosaki
  • Yasuko Aoki
  • Michi Shoji
  • Hajime Goto
  • Takeshi Saraya
  • Daisuke Kurai
  • Mitsuhiro Okazaki
  • Yoshio Kobayashi
  • Yasuhiro Katono
  • Akihiko Kawana
  • Katsu Saionji
  • Naoki Miyazawa
  • Yoshimi Sato
  • Yuji Watanuki
  • Makoto Kudo
  • Shigeru Ehara
  • Hiroki Tsukada
  • Yumiko Imai
  • Nobuei Watabe
  • Sakura Aso
  • Yasuo Honma
  • Hiroshige Mikamo
  • Yuka Yamagishi
  • Yoshio Takesue
  • Yasunao Wada
  • Tadahiro Nakamura
  • Noriko Mitsuno
  • Keiichi Mikasa
  • Kei Kasahara
  • Kenji Uno
  • Reiko Sano
  • Naoyuki Miyashita
  • Yukinori Kurokawa
  • Mariko Takaya
  • Masao Kuwabara
  • Yaeko Watanabe
  • Masao Doi
  • Satomi Shimizu
  • Kiyoshi Negayama
  • Junichi Kadota
  • Kazufumi Hiramatsu
  • Yoshitomo Morinaga
  • Junichi Honda
  • Masaki Fujita
  • Satoshi Iwata
  • Aikichi Iwamoto
  • Takayuki Ezaki
  • Shoichi Onodera
  • Shinya Kusachi
  • Kazuhiro Tateda
  • Michio Tanaka
  • Kyoichi Totsuka
  • Yoshihito Niki
  • Tetsuro Matsumoto
Surveillance

Abstract

For the purpose of nationwide surveillance of antimicrobial susceptibility of bacterial respiratory pathogens from patients in Japan, the Japanese Society of Chemotherapy (JSC) started a survey in 2006. From 2009, JSC continued the survey in collaboration with the Japanese Association for Infectious Diseases and the Japanese Society for Clinical Microbiology. The fourth-year survey was conducted during the period from January and April 2009 by the three societies. A total of 684 strains were collected from clinical specimens obtained from well-diagnosed adult patients with respiratory tract infections. Susceptibility testing was evaluable with 635 strains (130 Staphylococcus aureus, 127 Streptococcus pneumoniae, 4 Streptococcus pyogenes, 123 Haemophilus influenzae, 70 Moraxella catarrhalis, 78 Klebsiella pneumoniae, and 103 Pseudomonas aeruginosa). A maximum of 45 antibacterial agents including 26 β-lactams (four penicillins, three penicillins in combination with β-lactamase inhibitors, four oral cephems, eight parenteral cephems, one monobactam, five carbapenems, and one penem), four aminoglycosides, four macrolides (including ketolide), one lincosamide, one tetracycline, two glycopeptides, six fluoroquinolones, and one oxazolidinone were used for the study. Analysis was conducted at the central reference laboratory according to the method recommended by the Clinical and Laboratory Standard Institute (CLSI). Incidence of methicillin-resistant S. aureus (MRSA) was as high as 58.5 %, and that of penicillin-intermediate and penicillin-resistant S. pneumoniae (PISP and PRSP) was 6.3 % and 0.0 %, respectively. Among H. influenzae, 21.1 % of them were found to be β-lactamase-non-producing ampicillin (ABPC)-intermediately resistant (BLNAI), 18.7 % to be β-lactamase-non-producing ABPC-resistant (BLNAR), and 5.7 % to be β-lactamase-producing ABPC-resistant (BLPAR) strains. A high frequency (76.5 %) of β-lactamase-producing strains has been suspected in Moraxella catarrhalis isolates. Four (3.2 %) extended-spectrum β-lactamase-producing K. pneumoniae were found among 126 strains. Four isolates (2.5 %) of P. aeruginosa were found to be metallo-β-lactamase-producing strains, including three (1.9 %) suspected multi-drug resistant strains showing resistance against imipenem, amikacin, and ciprofloxacin. Continuous national surveillance of the antimicrobial susceptibility of respiratory pathogens is crucial to monitor changing patterns of susceptibility and to be able to update treatment recommendations on a regular basis.

Keywords

Surveillance Susceptibility Resistance Respiratory tract infection 

Notes

Acknowledgments

This investigation was supported by grants from following pharmaceutical companies (alphabetical order) : Abbott Japan Co., Ltd., Astellas Pharma Inc., Banyu Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Dainippon Sumitomo Pharma Co., Ltd., Glaxo SmithKline K.K., Kyorin Pharmaceutical Co., Ltd., Meiji Seika Kaisya, Ltd., Pfizer Japan Inc., Sanofi-Aventis K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, and Toyama Chemical Co., Ltd. We are grateful to T. Nakae and C. Yanagisawa at the Kitasato Institute (Tokyo, Japan) for their encouragement in microbiological testing and Y. Suzuki, H. Endo, and Y. Yamaguchi for their technical assistance in this surveillance.

Conflict of interest

Akira Watanabe is a consultant to Daiichi-Sankyo, Mitsubishi Tanabe Pharma corporation, Toyama Chemical, and Otsuka Pharmaceutical. A.W. has received a speaker’s honorarium from MSD Japan, Glaxo SmithKline K.K., Shionogi & Co. Ltd., Daiichi-Sankyo, Taisho Toyama Pharmaceutical, Dainippon Sumitomo Pharma and Pfizer Japan Inc.; and grant support from Kyorin Pharmaceutical, Shionogi & Co. Ltd., Taisho Pharmaceutical, Toyama Chemical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Taiho Pharma, and Meiji Seika Pharma. Shigeru Kohno has received a speaker’s honorarium from Glaxo SmithKline K.K., Shinogi & Co. Ltd., Astellas Pharma Inc., Daiichi-Sankyo, Taisho Toyama Pharmaceutical, Dainippon Sumitomo Pharma, Merck & Co., and Pfizer Japan Inc.; and grant support from Kyorin Pharmaceutical, Pfizer Japan Inc., Shinogi & Co. Ltd., Taisho Pharmaceutical, Toyama Chemical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Taiho Pharma, Meiji Seika Pharma, Astellas Pharma Inc., Merck & Co., Inc., Glaxo SmithKline K.K., and Chugai Pharmaceutical Co., Ltd. Tetsuya Matsumoto has received a speaker’s honorarium from Pfizer Japan Inc., Dainippon Sumitomo Pharma, and Meiji Seika Pharma. Naoto Koashi is an employee of Pfizer Japan Inc. Aikichi Iwamoto has received a speaker’s honorarium from Glaxo SmithKline K.K., Shinogi & Co. Ltd., Astellas Pharma Inc., Daiichi-Sankyo, Taisho Toyama Pharmaceutical, MSD Japan, Eiken Chemical Co. Ltd., Toyama Chemical, Janssen Pharmaceutical K.K., Abbott Japan Co. Ltd., ViiV Healthcare K.K., Bayer, Bristol-Myers Squibb, Torii Pharmaceutical Co. Ltd., Sysmex Corporation, and Pfizer Japan Inc.; and grant support from Toyama Chemical, Torii Pharmaceutical Co. Ltd., Astellas Pharma Inc., MSD Japan, Baxter, and Bristol-Myers Squibb. Keisuke Sunakawa has received a speaker’s honorarium from Meiji Seika Pharma, Taisho Toyama Pharmaceutical, and Shinogi & Co. Ltd. Hiroshige Mikamo has received a speaker’s honorarium from Astellas Pharma Inc., Daiichi-Sankyo, Taisho Toyama Pharmaceutical, Dainippon Sumitomo Pharma, and Pfizer Japan Inc. Satoshi Iwata has received a speaker’s honorarium from Meiji Seika Pharma, Pfizer Japan, Inc., Glaxo SmithKline K.K., Dainippon Sumitomo Pharma, MSD Japan, and Taisho Toyama Pharmaceutical Co., Ltd.; and grant support from Meiji Seika Pharma and Taisho Toyama Pharmaceutical. Yoshihito Niki has received a speaker’s honorarium from Astellas Pharma Inc., MSD Japan, Glaxo SmithKline K.K., Shionogi & Co. Ltd., Bayer, Daiichi-Sankyo, Taisho Toyama Pharmaceutical, Dainippon Sumitomo Pharma, and Pfizer Japan Inc.; and grant support from Astellas Pharma Inc., Kyorin Pharmaceutical, Shionogi & Co. Ltd., Taisho Pharmaceutical, Toyama Chemical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Taiho Pharma, Pfizer Japan Inc., Janssen Pharmaceutical K.K., and Meiji Seika Pharma.

References

  1. 1.
    Niki Y, Hanaki H, Matsumoto T, Yagisawa M, Kohno S, Aoki N, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2011;17(4):510–23.PubMedCrossRefGoogle Scholar
  2. 2.
    CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Wayne: Clinical and Laboratory Standards Institute; 2006. p. M7–A7Google Scholar
  3. 3.
    CLSI. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. Wayne: Clinical and Laboratory Standards Institute; 2008. p. M100–S18Google Scholar
  4. 4.
    Jenkins SG, Farrell DJ, Patel M, Lavin BS. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000–2003: PROTEKT US years 1–3. J Infect. 2005;51(5):355–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Barada K, Hanaki H, Ikeda S, Yamaguchi Y, Akama H, Nakae T, et al. Trends in the gentamicin and arbekacin susceptibility of methicillin-resistant Staphylococcus aureus and the genes encoding aminoglycoside-modifying enzymes. J Infect Chemother. 2007;13(2):74–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Mochizuki T, Okamoto N, Yagishita T, Takuhiro K, Mashiko K, Ogawa F, et al. Analysis of antimicrobial drug resistance of Staphylococcus aureus strains by WHONET 5: microbiology laboratory database software. J Nihon Med Sch. 2004;71(5):345–51.CrossRefGoogle Scholar
  7. 7.
    Hasegawa K, Kobayashi R, Takada E, Ono A, Chiba N, Morozumi M, et al. High prevalence of type b beta-lactamase-non-producing ampicillin-resistant Haemophilus influenzae in meningitis: the situation in Japan where Hib vaccine has not been introduced. J Antimicrob Chemother. 2006;57(6):1077–82.PubMedCrossRefGoogle Scholar
  8. 8.
    Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett. 2000;184(1):53–6.PubMedGoogle Scholar
  9. 9.
    Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Uehara N, Yasujima M, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn J Antibiot. 2007;60(6):344–77.PubMedGoogle Scholar
  10. 10.
    Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Kanda M, et al. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,919 clinical isolates obtained from 72 centers in 2007. Jpn J Antibiot. 2009;62(4):346–70.PubMedGoogle Scholar

Copyright information

© Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases 2012

Authors and Affiliations

  • Akira Watanabe
    • 1
  • Katsunori Yanagihara
    • 1
    • 26
    Email author
  • Tetsuya Matsumoto
    • 1
  • Shigeru Kohno
    • 1
    • 26
  • Nobuki Aoki
    • 1
    • 17
  • Toyoko Oguri
    • 1
  • Junko Sato
    • 1
  • Tetsuro Muratani
    • 1
  • Morimasa Yagisawa
    • 1
  • Kazuhiko Ogasawara
    • 1
  • Naoto Koashi
    • 1
  • Tsuneo Kozuki
    • 1
  • Akira Komoto
    • 1
  • Yoshisaburo Takahashi
    • 1
  • Toshikatsu Tsuji
    • 1
  • Michinori Terada
    • 1
  • Kunio Nakanishi
    • 1
  • Rikizo Hattori
    • 1
  • Yukio Hirako
    • 1
  • Akinori Maruo
    • 1
  • Shinichi Minamitani
    • 1
  • Kohei Morita
    • 1
  • Tomotaro Wakamura
    • 1
  • Keisuke Sunakawa
    • 1
  • Hideaki Hanaki
    • 2
  • Yoshinobu Ohsaki
    • 3
  • Yasuhito Honda
    • 4
  • Shoichi Sasaoka
    • 5
  • Hiroaki Takeda
    • 6
  • Hideki Ikeda
    • 7
  • Atsuko Sugai
    • 7
  • Makoto Miki
    • 8
  • Susumu Nakanowatari
    • 8
  • Hiroshi Takahashi
    • 9
  • Mutsuko Utagawa
    • 9
  • Nobuyuki Kobayashi
    • 10
  • Jin Takasaki
    • 10
  • Hisami Konosaki
    • 10
  • Yasuko Aoki
    • 11
  • Michi Shoji
    • 11
  • Hajime Goto
    • 12
  • Takeshi Saraya
    • 12
  • Daisuke Kurai
    • 12
  • Mitsuhiro Okazaki
    • 12
  • Yoshio Kobayashi
    • 13
  • Yasuhiro Katono
    • 13
  • Akihiko Kawana
    • 14
  • Katsu Saionji
    • 14
  • Naoki Miyazawa
    • 15
  • Yoshimi Sato
    • 15
  • Yuji Watanuki
    • 15
  • Makoto Kudo
    • 15
  • Shigeru Ehara
    • 15
  • Hiroki Tsukada
    • 16
  • Yumiko Imai
    • 16
  • Nobuei Watabe
    • 16
  • Sakura Aso
    • 16
  • Yasuo Honma
    • 17
  • Hiroshige Mikamo
    • 18
  • Yuka Yamagishi
    • 18
  • Yoshio Takesue
    • 19
  • Yasunao Wada
    • 19
  • Tadahiro Nakamura
    • 20
  • Noriko Mitsuno
    • 20
  • Keiichi Mikasa
    • 21
  • Kei Kasahara
    • 21
  • Kenji Uno
    • 21
  • Reiko Sano
    • 21
  • Naoyuki Miyashita
    • 22
  • Yukinori Kurokawa
    • 22
  • Mariko Takaya
    • 22
  • Masao Kuwabara
    • 23
  • Yaeko Watanabe
    • 23
  • Masao Doi
    • 23
  • Satomi Shimizu
    • 22
  • Kiyoshi Negayama
    • 24
  • Junichi Kadota
    • 1
    • 25
  • Kazufumi Hiramatsu
    • 25
  • Yoshitomo Morinaga
    • 26
  • Junichi Honda
    • 27
  • Masaki Fujita
    • 28
  • Satoshi Iwata
    • 1
  • Aikichi Iwamoto
    • 1
  • Takayuki Ezaki
    • 1
  • Shoichi Onodera
    • 1
  • Shinya Kusachi
    • 1
  • Kazuhiro Tateda
    • 1
  • Michio Tanaka
    • 1
  • Kyoichi Totsuka
    • 1
  • Yoshihito Niki
    • 1
  • Tetsuro Matsumoto
    • 1
  1. 1.The Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases and Japanese Society for Clinical Microbiology, c/o Japanese Society of ChemotherapyTokyoJapan
  2. 2.The Kitasato InstituteTokyoJapan
  3. 3.Asahikawa Medical UniversityAsahikawaJapan
  4. 4.Sapporo Medical Center NTT ECSapporoJapan
  5. 5.Muroran General HospitalMuroranJapan
  6. 6.Yamagata Saisei HospitalYamagataJapan
  7. 7.Sanyudo HospitalYonezawaJapan
  8. 8.Japanese Red Cross Sendai HospitalSendaiJapan
  9. 9.Saka General HospitalShiogamaJapan
  10. 10.National Center for Global Health and MedicineTokyoJapan
  11. 11.National Hospital Organization Tokyo Medical CenterTokyoJapan
  12. 12.Kyorin University HospitalMitakaJapan
  13. 13.Keio University HospitalTokyoJapan
  14. 14.National Defense Medical CollegeTokorozawaJapan
  15. 15.Yokohama City University HospitalYokohamaJapan
  16. 16.Niigata City General HospitalNiigataJapan
  17. 17.Shinrakuen HospitalNiigataJapan
  18. 18.Aichi Medical University HospitalAichiJapan
  19. 19.Hyogo College of MedicineNishinomiyaJapan
  20. 20.Osaka City General HospitalOsakaJapan
  21. 21.Center for Infectious Diseases, Nara Medical UniversityKashiharaJapan
  22. 22.Kawasaki Medical School HospitalKurashikiJapan
  23. 23.Hiroshima Prefectural HospitalHiroshimaJapan
  24. 24.Kagawa University HospitalKagawaJapan
  25. 25.Oita University Faculty of MedicineYufuJapan
  26. 26.Nagasaki University School of MedicineNagasakiJapan
  27. 27.St. Mary’s HospitalKurumeJapan
  28. 28.Fukuoka University Faculty of MedicineFukuokaJapan

Personalised recommendations